<DOC>
	<DOCNO>NCT00219375</DOCNO>
	<brief_summary>The purpose study confirm efficacy safety sivelestat patient acute lung injury associate systemic inflammatory response syndrome . The result compare study conventional treatment without sivelestat .</brief_summary>
	<brief_title>Study Sivelestat Sodium Hydrate Acute Lung Injury ( ALI ) Associated With Systemic Inflammatory Response Syndrome ( SIRS ) Japan</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Sivelestat</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>1 . Patients systemic inflammatory response syndrome ( SIRS ) 2 . Patients acute lung injury ( ALI ) assess use criterion specify AmericanEuropean Consensus Conference 3 . Within 72 hour onset lung injury 4 . Other inclusion criterion specify protocol 1 . Already administrated Sivelestat enrollment study 2 . Neuromuscular disease impair spontaneous ventilation 3 . Severe central nervous system disease 4 . Bone marrow transplant 5 . Lung transplant 6 . Severe chronic liver disease 7 . Neutropenia ( neutrophil count : 1000/mm3 ) 8 . Other exclusion criterion specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>sivelestat sodium hydrate</keyword>
	<keyword>acute lung injury</keyword>
	<keyword>systemic inflammatory response syndrome</keyword>
	<keyword>Elaspol</keyword>
	<keyword>Acute Lung Injury ( ALI ) Associated With Systemic Inflammatory Response Syndrome ( SIRS )</keyword>
</DOC>